Roche
9115 Hague Road
Indianapolis
Indiana
46256
United States
Tel: 317-521-2000
Fax: 317-521-2090
Website: http://www.roche.com/
About Roche
Founded in 1896, Roche is a global pioneer in pharmaceuticals and diagnostics and is the world’s largest biotech company, focused on advancing science to improve people’s lives. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics. The Diagnostics division develops and produces medical tests that provide information to help healthcare professionals find the right treatment for patients and deliver the best patient care to improve, prolong and save lives.
We offer a wide range of research and in vitro (outside the body) diagnostic tools that help in the early detection, prevention, diagnosis and treatment of diseases like congestive heart failure, HIV, hepatitis and diabetes, as well as medical conditions like fertility and blood coagulation. These products and services are used by researchers, physicians, patients, healthcare facilities and laboratories around the world.
Roche Diagnostics has its North American headquarters in Indianapolis. The Roche campus, located at 96th Street and Hague Road, spans about 155 acres and is home to U.S. research and development, laboratory, manufacturing, distribution, IT and administrative operations. The campus supports six diagnostics business areas: Diabetes Care, Centralized Diagnostics, Sequencing and Life Science, Molecular Diagnostics, Point of Care Diagnostics and Tissue Diagnostics. About 4,000 employees report into Indianapolis, with about 2,900 working onsite.
Roche Molecular Solutions, one of the global business areas within Roche Diagnostics, brings together the diagnostic power of molecular, tissue and sequencing technologies.
With the goal of revolutionizing diagnostic decisions through integrated solutions, Roche Molecular Solutions brings together the latest technologies withinmolecular diagnostics (polymerase chain reaction or PCR-based testing), tissue diagnostics (tissue biopsy testing) and sequencing solutions (next-generation DNA and RNA sequence-based testing) to advance the standard of care for everyone.
California Location:
4300 Hacienda Drive
Pleasanton, California 94588
United States
Tel: 925-730-8000
Fax: 925-225-0479
1739 articles with Roche
-
Roche subsidiary Genentech snaps up Jecure and its portfolio of preclinical NLRP3 inhibitors aimed at serious inflammatory diseases.
-
Roche launches first IVD pan-TRK immunohistochemistry assay
11/27/2018
The VENTANA pan-TRK (EPR17341) Assay[1] is the first assay of its type to detect tropomyosin receptor kinase (TRK) with anticipated use across multiple solid tumor types
-
Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test
11/27/2018
Daiichi Sankyo Company, Limited announced today that it has entered into an agreement with Roche to collaborate on the development of a new HER2 low companion diagnostic test.
-
AbbVie could be eyeing another potential billion dollars of annual revenue following the accelerated approval of Venclexta for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older or who cannot tolerate intensive chemotherapy.
-
Less than a week ago, Roche snagged regulatory approval for Xofluza, a single-dose oral medication, the first new flu treatment approved in 20 years. Now, new research indicates that llamas, the doe-eyed South American pack animal, may hold the key to flu vaccines.
-
Tesaro, located in Waltham, Mass., is rumored to be up for sale. The rumors caused shares to rocket as much as 39 percent on Friday, but it’s not the first time rumors have floated that the company might be on the auction block.
-
Rob Dunn, a professor of applied ecology at North Carolina State University in Raleigh recently wrote a book, Never Home Alone. In this book, he describes how millions of microorganisms, bacteria, fungi, viruses, parasites and insects live in your home—and in and on your body.
-
BioSpace Movers and Shakers Nov. 12
11/12/2018
Biopharma companies name new members of their leadership teams. Who made big moves this week? -
In Recognition of National Diabetes Awareness Month and Veteran's Day, Roche Honors the One in Four Veterans Living With Diabetes at iHeartCountry One Night For Our Military Concert
11/7/2018
Raising Awareness for the More Than 30 Million Americans with Diabetes
-
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
-
Days after Novartis axed one-fifth of its research programs, the Swiss pharma giant said it intends to seek regulatory approval for 60 new treatments between 2019 and 2021.
-
The U.S. FDA approved Pfizer’s Lorbrena (lorlatinib) for ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients whose disease hasn’t progressed on crizotinib and at least one other ALK inhibitor or for patients whose disease has progressed on alectinib or ceritinib as the first AL...
-
Indianapolis-based Eli Lilly announced that its diabetes drug Trulicity (dulaglutide) reduced major adverse cardiovascular events (MACE) in its REWIND clinical trial.
-
Biopharma companies set to release financial reports next week have reported positive news in recent months.
-
In what appears to be a trend, big pharma company AbbVie is leasing 479,000 square feet of space inBioMed Realty’s Gateway of Pacific project in South San Francisco.
-
A study evaluated fixed-duration the two companies’ Venclexta/Venclyxto (venetoclax) in combination with Genentech’s Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions.
-
Roche Diagnostics to replace CoaguChek® XS PT Test Strips
10/31/2018
This notification supplements previous Urgent Medical Device Correction (UMDC) communications initially issued by Roche Diagnostics on September 12, 2018 and updated on October 17, 2018.
-
To suggest that the pharma industry is a reluctant partner in President Donald Trump’s attempts to decrease drug prices is to overstate the fact. But now the industry appears to be pushing back, at least a little bit.
-
Denmark-based Genmab A/S released topline data from its Phase III MAIA trial of a drug it licensed to Johnson & Johnson’s Janssen Biotech, Darzalex (daratumumab).
-
Four former Genentech employees have been indicted by a federal grand jury for the alleged theft of company trade secrets in order to help a company set up in Taiwan develop drugs similar to those made by the Roche subsidiary.